Zacks Small Cap Research on MSN

COCP: CDI-988 data to be presented at ICAR 2026

By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update CDI-988 to be Featured at ICAR2026 On February 19, 2026, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced that initial ...
Seeking Alpha

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and ...

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by ...

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 ...
Nasdaq

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral ...